基线糖皮质激素对非小细胞肺癌PD-(L)1阻断疗效的影响
该研究基于纪念斯隆凯特琳癌症中心和Gustave Roussy癌症中心640例接受单药PD-(L)1阻断的晚期非小细胞肺癌患者,发现14%的患者在治疗开始时每日使用≥10 mg泼尼松等效剂量的糖皮质激素。结论推荐在启动PD-(L)1阻断时谨慎使用糖皮质激素。
要点
- 基线使用≥10 mg泼尼松等效剂量与PD-(L)1阻断后更差的ORR、PFS和OS相关。
- 多因素分析中,基线激素仍显著降低PFS(HR 1.3)和OS(HR 1.7)。
- 启动PD-(L)1阻断时,应审慎评估并使用糖皮质激素。
核心结论
- 基线使用≥10 mg泼尼松等效剂量的糖皮质激素与非小细胞肺癌患者接受PD-(L)1阻断后更差的疗效和生存相关。
- 建议在启动PD-(L)1阻断时谨慎使用糖皮质激素。
研究设计与样本
- 研究为回顾性真实世界研究,纳入两个独立中心(纪念斯隆凯特琳癌症中心和Gustave Roussy癌症中心)的640例晚期非小细胞肺癌患者。
- 患者均为PD-(L)1初治并接受单药PD-(L)1阻断治疗。
- 通过查阅临床和药房记录确定治疗开始时糖皮质激素使用情况。
- 采用Cox比例风险回归模型和逻辑回归进行多因素分析。
主要发现
- 糖皮质激素常见指征为呼吸困难(33%)、乏力(21%)和脑转移(19%)。
- 在两个独立队列(纪念斯隆凯特琳癌症中心n=455;Gustave Roussy癌症中心n=185)中,基线糖皮质激素均与客观缓解率、无进展生存和总生存下降相关。
临床怎么用
- 在启动PD-(L)1阻断前,应评估患者是否正在使用≥10 mg泼尼松等效剂量的糖皮质激素。
- 对于需使用糖皮质激素的患者,应与肿瘤内科医生共同权衡免疫检查点抑制剂的使用时机。
局限性
- 研究为回顾性真实世界分析,可能存在未测量的混杂因素。
- 临床试验通常排除基线使用糖皮质激素的患者,本研究结果需在前瞻性研究中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Treatment with programmed cell death-1 or programmed death ligand 1 (PD-(L)1) inhibitors is now standard therapy for patients with lung cancer. The immunosuppressive effect of corticosteroids may reduce efficacy of PD-(L)1 blockade. On-treatment corticosteroids for treatment of immune-related adverse events do not seem to affect efficacy, but the potential impact of baseline corticosteroids at the time of treatment initiation is unknown. Clinical trials typically excluded patients who received baseline corticosteroids, which led us to use real-world data to examine the effect of corticosteroids at treatment initiation. METHODS: We identified patients who were PD-(L)1-naïve with advanced non-small-cell lung cancer from two institutions-Memorial Sloan Kettering Cancer Center and Gustave Roussy Cancer Center-who were treated with single-agent PD-(L)1 blockade. Clinical and pharmacy records were reviewed to identify corticosteroid use at the time of beginning anti-PD-(L)1 therapy. We performed multivariable analyses using Cox proportional hazards regression model and logistic regression. RESULTS: Ninety (14%) of 640 patients treated with single-agent PD-(L)1 blockade received corticosteroids of ≥ 10 mg of prednisone equivalent daily at the start of the PD-(L)1 blockade. Common indications for corticosteroids were dyspnea (33%), fatigue (21%), and brain metastases (19%). In both independent cohorts, Memorial Sloan Kettering Cancer Center (n = 455) and Gustave Roussy Cancer Center (n = 185), baseline corticosteroids were associated with decreased overall response rate, progression-free survival, and overall survival with PD-(L)1 blockade. In a multivariable analysis of the pooled population, adjusting for smoking history, performance status, and history of brain metastases, baseline corticosteroids remained significantly associated with decreased progression-free survival (hazard ratio, 1.3; P = .03), and overall survival (hazard ratio, 1.7; P < .001). CONCLUSION: Baseline corticosteroid use of ≥ 10 mg of prednisone equivalent was associated with poorer outcome in patients with non-small-cell lung cancer who were treated with PD-(L)1 blockade. Prudent use of corticosteroids at the time of initiating PD-(L)1 blockade is recommended.
引用
- Arbour KC, Mezquita L, Long N, et al. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol. 2018. PMID: 30125216. doi:10.1200/JCO.2018.79.0006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。